Cardiovascular
Losartan
PBAC's latest decision on Losartan: Recommended (2010). Considered for treatment of hypertension.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2010 → 2010
Eligible population
patients with hypertension
- Therapy area
- Cardiovascular
- Line of therapy
- Any
- Evidence base
- RCT
- Primary endpoint
- Other
- Key trials
- Oparil 1998, Dang 2006, Fogari 2001, Kassler-Taub 1998, Koh 2004, Oparil 2001, LIFE, RENAAL, INDT, IRMA-2
- Comparator
- irbesartan
- Economic model
- Cost-minimisation
- ICER note
- Cost-minimisation analysis: no ICER calculated by design
Open on full dashboard →